T1	PROC 46 60	Ensayo clínico
#1	AnnotatorNotes T1	C0008976; Clinical Trials; Research Activity
T2	DISO 78 94	cáncer de hígado
#2	AnnotatorNotes T2	C0345904; Malignant neoplasm of liver; Neoplastic Process
T3	PROC 111 119	extirpar
#3	AnnotatorNotes T3	C0728940; Excision; Therapeutic or Preventive Procedure
T4	PROC 129 136	cirugía
#4	AnnotatorNotes T4	C0543467; Operative Surgical Procedures; Therapeutic or Preventive Procedure
T5	CHEM 216 245	medicamentos en investigación
#5	AnnotatorNotes T5	C0013230; Investigational New Drugs; Pharmacologic Substance
T6	PROC 148 188	se investiga la seguridad, tolerabilidad
T7	CHEM 257 269	tremelimumab
#6	AnnotatorNotes T7	C2351038; tremelimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T8	DISO 887 896	infección
#7	AnnotatorNotes T8	C0009450; Communicable Diseases; Disease or Syndrome | C3714514; Infection; Pathologic Function
T9	CHEM 323 335	medicamentos
#8	AnnotatorNotes T9	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T10	PROC 357 368	monoterapia
#9	AnnotatorNotes T10	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T11	PROC 465 500	Estudio de seguridad, tolerabilidad
T12	CHEM 535 547	tremelimumab
#10	AnnotatorNotes T12	C2351038; tremelimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T13	PROC 565 576	monoterapia
#11	AnnotatorNotes T13	C4763675; Single Agent Therapy; Therapeutic or Preventive Procedure
T14	DISO 610 633	carcinoma hepatocelular
#12	AnnotatorNotes T14	C2239176; Liver carcinoma; Neoplastic Process
T15	ANAT 680 686	hígado
#13	AnnotatorNotes T15	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T16	DISO 713 736	Carcinoma hepatocelular
#14	AnnotatorNotes T16	C2239176; Liver carcinoma; Neoplastic Process
T17	PROC 814 825	Diagnóstico
#15	AnnotatorNotes T17	C0011900; Diagnosis; Diagnostic Procedure
T18	DISO 1026 1038	intolerancia
#16	AnnotatorNotes T18	C0277585; Intolerance to drug; Pathologic Function
T19	DISO 840 863	carcinoma hepatocelular
#17	AnnotatorNotes T19	C2239176; Liver carcinoma; Neoplastic Process
T20	DISO 917 940	virus de la hepatitis B
T21	DISO 946 957	hepatitis C
#18	AnnotatorNotes T21	C0019196; Hepatitis C; Disease or Syndrome
T22	DISO 996 1023	progresión de la enfermedad
#19	AnnotatorNotes T22	C0242656; Disease Progression; Pathologic Function
T23	CHEM 1042 1051	sorafenib
#20	AnnotatorNotes T23	C1516119; sorafenib; Organic Chemical · Pharmacologic Substance
T24	PROC 1079 1090	tratamiento
#21	AnnotatorNotes T24	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T25	PROC 1158 1171	inmunoterapia
#22	AnnotatorNotes T25	C0021083; Immunotherapy; Therapeutic or Preventive Procedure
T26	DISO 1175 1197	Encefalopatía hepática
#23	AnnotatorNotes T26	C0019151; Hepatic Encephalopathy; Disease or Syndrome
T27	DISO 1216 1225	asterixis
#24	AnnotatorNotes T27	C0232766; Asterixis; Sign or Symptom
T28	DISO 1229 1258	Hemorragia digestiva varicosa
T29	PROC 1302 1315	quimioterapia
#25	AnnotatorNotes T29	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T30	PROC 1317 1330	inmunoterapia
#26	AnnotatorNotes T30	C0021083; Immunotherapy; Therapeutic or Preventive Procedure
T31	PROC 1333 1361	terapia biológica u hormonal
T32	CHEM 1353 1361	hormonal
#27	AnnotatorNotes T32	C0019932; Hormones; Hormone
T33	PROC 1383 1405	tratamiento del cáncer
#28	AnnotatorNotes T33	C0920425; cancer treatment; Therapeutic or Preventive Procedure
T34	DISO 1409 1452	Trastornos autoinmunitarios o inflamatorios
T35	CHEM 1538 1567	medicamentos inmunosupresores
T36	ANAT 88 94	hígado
#29	AnnotatorNotes T36	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T37	DISO 670 686	Cancer de hígado
#30	AnnotatorNotes T37	C0345904; Malignant neoplasm of liver; Neoplastic Process
T38	CHEM 524 532	MEDI4736
#31	AnnotatorNotes T38	C3641122; MEDI4736; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T39	ANAT 620 633	hepatocelular
#32	AnnotatorNotes T39	C0227525; Hepatocyte; Cell
T40	ANAT 723 736	hepatocelular
#33	AnnotatorNotes T40	C0227525; Hepatocyte; Cell
T41	ANAT 850 863	hepatocelular
#34	AnnotatorNotes T41	C0227525; Hepatocyte; Cell
T42	CHEM 1095 1104	sorafenib
#35	AnnotatorNotes T42	C1516119; sorafenib; Organic Chemical · Pharmacologic Substance
T43	ANAT 1189 1197	hepática
#36	AnnotatorNotes T43	C0023884; Liver; Body Part, Organ, or Organ Component | C1278929; Entire liver; Body Part, Organ, or Organ Component
T44	DISO 1399 1405	cáncer
#37	AnnotatorNotes T44	C0006826; Malignant Neoplasms; Neoplastic Process
T45	CHEM 246 254	MEDI4736
#38	AnnotatorNotes T45	C3641122; MEDI4736; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T46	Date 13 17	2015
T47	LIVB 64 73	pacientes
#39	AnnotatorNotes T47	C0030705; Patients; Patient or Disabled Group
T48	Neg_cue 99 101	no
T50	LIVB 431 440	pacientes
#40	AnnotatorNotes T50	C0030705; Patients; Patient or Disabled Group
T51	LIVB 596 605	pacientes
#41	AnnotatorNotes T51	C0030705; Patients; Patient or Disabled Group
T53	LIVB 766 793	Pacientes hombres o mujeres
#42	AnnotatorNotes T53	C0030705; Patients; Patient or Disabled Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T56	Age 797 810	18 años o más
T58	Neg_cue 883 886	sin
T60	LIVB 965 974	pacientes
#43	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Neg_cue 1066 1075	rechazado
T62	Date 1528 1534	actual
T63	Duration 1571 1593	los 14 días anteriores
A1	Assertion T3 Negated
A2	Assertion T4 Negated
A3	Assertion T8 Negated
A4	Assertion T24 Negated
A5	Status T18 History_of
A6	Status T25 History_of
A7	Status T28 History_of
A8	Status T34 History_of
A9	Status T35 History_of
#44	AnnotatorNotes T6	C3274448; Tolerability Study; Research Activity + C1705187; Safety Study; Research Activity
#45	AnnotatorNotes T11	C3274448; Tolerability Study; Research Activity + C1705187; Safety Study; Research Activity
#46	AnnotatorNotes T20	C0019163; Hepatitis B; Disease or Syndrome
#47	AnnotatorNotes T35	C0021081; Immunosuppressive Agents; Immunologic Factor · Pharmacologic Substance
#48	AnnotatorNotes T62	C0521116; Current (present time); Temporal Concept 
T49	Neg_cue 864 866	no
T52	Quantifier_or_Qualifier 867 876	resecable
A10	Assertion T52 Negated
#49	AnnotatorNotes T52	C1514888; Resectable; Qualitative Concept
T54	Neg_cue 634 636	no
T55	Quantifier_or_Qualifier 637 646	resecable
A11	Assertion T55 Negated
#50	AnnotatorNotes T55	C1514888; Resectable; Qualitative Concept
T57	Quantifier_or_Qualifier 897 909	concomitante
A12	Assertion T57 Negated
#51	AnnotatorNotes T57	C0521115; Simultaneous; Temporal Concept
R1	Has_Quantifier_or_Qualifier Arg1:T8 Arg2:T57	
R2	Negation Arg1:T58 Arg2:T8	
R3	Negation Arg1:T58 Arg2:T57	
R4	Negation Arg1:T49 Arg2:T52	
A13	Assertion T42 Negated
T59	Quantifier_or_Qualifier 1362 1374	concomitante
#52	AnnotatorNotes T59	C0521115; Simultaneous; Temporal Concept
R5	Experiences Arg1:T47 Arg2:T2	
R6	Location_of Arg1:T36 Arg2:T2	
R7	Negation Arg1:T48 Arg2:T3	
R8	Negation Arg1:T48 Arg2:T4	
T64	Observation 99 136	no se puede extirpar mediante cirugía
#53	AnnotatorNotes T64	C4039777; Tumor surgically unresectable; Finding
R9	Has_Quantifier_or_Qualifier Arg1:T2 Arg2:T64	
R11	Experiences Arg1:T47 Arg2:T3	
R12	Experiences Arg1:T47 Arg2:T4	
R13	Experiences Arg1:T47 Arg2:T5	
R14	Experiences Arg1:T47 Arg2:T45	
R15	Experiences Arg1:T47 Arg2:T7	
R16	Used_for Arg1:T9 Arg2:T10	
R17	Experiences Arg1:T50 Arg2:T9	
T65	PROC 336 349;372 386	administrados en combinación
#54	AnnotatorNotes T65	C0013218; Combination Drug Therapy; Therapeutic or Preventive Procedure
R18	Used_for Arg1:T9 Arg2:T65	
R19	Experiences Arg1:T50 Arg2:T65	
T66	Observation 303 309	efecto
#55	AnnotatorNotes T66	C1518681; Outcome of Therapy; Finding (?)
R20	Causes Arg1:T9 Arg2:T66	
R21	Experiences Arg1:T50 Arg2:T66	
R22	Used_for Arg1:T38 Arg2:T13	
R23	Used_for Arg1:T12 Arg2:T13	
R24	Combined_with Arg1:T38 Arg2:T12	
R25	Experiences Arg1:T51 Arg2:T38	
R26	Experiences Arg1:T51 Arg2:T12	
R27	Experiences Arg1:T51 Arg2:T14	
R28	Location_of Arg1:T39 Arg2:T14	
R29	Negation Arg1:T54 Arg2:T55	
R30	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T55	
R31	Location_of Arg1:T15 Arg2:T37	
R32	Location_of Arg1:T40 Arg2:T16	
R33	Location_of Arg1:T41 Arg2:T19	
R34	Has_Quantifier_or_Qualifier Arg1:T19 Arg2:T52	
R35	Overlap Arg1:T19 Arg2:T8	
R36	Overlap Arg1:T19 Arg2:T20	
R37	Overlap Arg1:T19 Arg2:T21	
A14	Assertion T20 Negated
A15	Assertion T21 Negated
R38	Negation Arg1:T58 Arg2:T20	
R39	Negation Arg1:T58 Arg2:T21	
R40	Experiences Arg1:T60 Arg2:T22	
R41	Causes Arg1:T23 Arg2:T18	
R43	Negation Arg1:T61 Arg2:T24	
R44	Used_for Arg1:T42 Arg2:T24	
R45	Experiences Arg1:T60 Arg2:T24	
R46	Location_of Arg1:T43 Arg2:T26	
R47	Causes Arg1:T26 Arg2:T27	
T67	Quantifier_or_Qualifier 1259 1265	activa
#56	AnnotatorNotes T67	C0679217; Active State; Idea or Concept
R48	Has_Quantifier_or_Qualifier Arg1:T28 Arg2:T67	
R49	Used_for Arg1:T32 Arg2:T31	
R50	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T59	
R51	Has_Quantifier_or_Qualifier Arg1:T30 Arg2:T59	
R52	Has_Quantifier_or_Qualifier Arg1:T29 Arg2:T59	
#57	AnnotatorNotes T34	C0004364; Autoimmune Diseases; Disease or Syndrome | C1290884; Inflammatory disorder; Disease or Syndrome
T68	Quantifier_or_Qualifier 1453 1460	activos
#58	AnnotatorNotes T68	C0679217; Active State; Idea or Concept
R53	Has_Quantifier_or_Qualifier Arg1:T34 Arg2:T68	
R54	Overlap Arg1:T35 Arg2:T62	
R55	Overlap Arg1:T35 Arg2:T63	
#59	AnnotatorNotes T31	C0005527; Biological Response Modifier Therapy; Therapeutic or Preventive Procedure | C0279025; Hormone Therapy; Therapeutic or Preventive Procedure
A16	Experiencer T51 Patient
A17	Experiencer T60 Patient
A18	Experiencer T47 Patient
A19	Experiencer T50 Patient
A20	Experiencer T53 Patient
